- Home
- PIII vs ELEV Comparison
PIII vs ELEV Comparison
Compare PIII & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ELEV
- Stock Information
- Founded
- PIII 2015
- ELEV 2019
- Country
- PIII United States
- ELEV United States
- Employees
- PIII N/A
- ELEV N/A
- Industry
- PIII Medical/Nursing Services
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ELEV Health Care
- Exchange
- PIII Nasdaq
- ELEV Nasdaq
- Market Cap
- PIII 37.5M
- ELEV 37.6M
- IPO Year
- PIII N/A
- ELEV 2021
- Fundamental
- Price
- PIII $0.21
- ELEV $0.61
- Analyst Decision
- PIII Buy
- ELEV Buy
- Analyst Count
- PIII 3
- ELEV 6
- Target Price
- PIII $2.38
- ELEV $7.20
- AVG Volume (30 Days)
- PIII 1.3M
- ELEV 1.3M
- Earning Date
- PIII 03-27-2025
- ELEV 03-05-2025
- Dividend Yield
- PIII N/A
- ELEV N/A
- EPS Growth
- PIII N/A
- ELEV N/A
- EPS
- PIII N/A
- ELEV N/A
- Revenue
- PIII $1,476,630,000.00
- ELEV N/A
- Revenue This Year
- PIII $21.45
- ELEV N/A
- Revenue Next Year
- PIII N/A
- ELEV N/A
- P/E Ratio
- PIII N/A
- ELEV N/A
- Revenue Growth
- PIII 25.38
- ELEV N/A
- 52 Week Low
- PIII $0.17
- ELEV $0.50
- 52 Week High
- PIII $1.20
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- PIII 49.40
- ELEV 43.44
- Support Level
- PIII $0.20
- ELEV $0.64
- Resistance Level
- PIII $0.25
- ELEV $0.72
- Average True Range (ATR)
- PIII 0.02
- ELEV 0.05
- MACD
- PIII 0.00
- ELEV -0.00
- Stochastic Oscillator
- PIII 46.32
- ELEV 18.41
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.